NCT04092205已完成2 期
EMERA007 - An Open Label, Active-treatment Controlled, Phase 2a Pilot Study to Explore Safety and Efficacy of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation
EmeraMed1 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2019年11月21日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- Incidence of Treatment-Emergent Adverse Events
研究概览
简要总结
A pilot study to explore safety and efficacy of NBMI treatment in patients with Beta Thalassemia Major requiring iron chelation
Investigational product: NBMI (N1,N3-bis(2-mercaptoethyl) isophthalamide), INN: Emeramide
Indication: Beta Thalassemia Major
详细描述
Patients with iron overload, not controlled with current therapy will be enrolled to the study. After initial treatment with standard chelation therapy (deferasirox), patients will receive 600 mg daily dose of emeramide (NBMI) for 28 days. After that follow up period on standard treatment with deferasirox shall follow.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient has clinically confirmed documented diagnosis of Beta Thalassemia Major, according to the current clinical criteria, and are on blood transfusions.
- •Patient has been on a stable maintaince therapy with deferasirox for at least during last 3 months.
- •Patients current chelation therapy is considered inadequate, meaning that there is evidence from clinical monitoring that chronic iron overload is present (e.g. serum ferritin >1,000 µg/l), for at least during the last 3 months.
- •The ferritin level has been stable with max 10% difference between max-to-low, and the iron chelator treatment dose has been unchanged during the last 3 months
- •Patient is aged 18 years or older at screening.
- •Female patients are only eligible for the study if they are either surgically sterile or at least 2 years postmenopausal, or have a negative result of serum hCG test at screening and if willing to use acceptable, effective methods of contraception during the trial and for three month after the end of trial participation as defined inpoint 7.
- •of this the protocol.
- •Male patients must either be surgically sterile or he and his female spouse/partner who is of childbearing potential must be willing to use highly effective methods of contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at screening and continuing throughout the study.
- •Patient is fluent in the local language and provides written informed consent.
排除标准
- •Known history or presence of clinically significant other, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
- •Known or suspected allergy hypersensitivity or idiosyncratic reaction to NBMI or any other drug substances with similar activity.
- •History of drug or alcohol addiction requiring treatment.
- •History of malabsorption within the last year or presence of clinically significant gastrointestinal disease or surgery that may affect drug bioavailability, including but not limited to cholecystectomy.
- •Presence of hepatic or renal dysfunction. (SGOT and SGPT and bilirubin > X3 (3 fold) UNL. creatinine > 1.5mg/dl).
- •Female patient who is pregnant (serum hCG level consistent with pregnancy diagnosis); or breastfeeding.
- •Participation in a clinical trial that involved administration of an investigational medicinal product within 90 days prior to drug administration, or recent participation in a clinical investigation that, in the opinion of the Investigator, would jeopardize subject safety or the integrity of the study results.
- •Have clinically significant abnormal laboratory values (e.g. liver enzymes).
- •Have clinically significant findings from a physical examination (e.g. fever).
- •Patient has Inflammatory disorders, liver disease such as hepatitis, malignancy or other condition that could influence ferritine levels and therefore validity of study results.
研究组 & 干预措施
Experimental: Treatment
Experimental
28 days treatment with NBMI 600 mg/day
干预措施: Emeramide (Drug)
结局指标
主要结局
Incidence of Treatment-Emergent Adverse Events
时间窗: 28 days
The safety assessment is based on the number, type and severity of adverse events. The incidence of adverse events will be summarized by organ class, severity and duration.
次要结局
- Change in serum ferritin levels(28 days)
- Change in iron load in the liver and heart(28 days)
- Percentage of NBMI-treated patients who will develop a response(28 days)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
A Study of IMR-687 in Subjects With Beta Thalassemiaβ ThalassemiaNCT04411082Cardurion Pharmaceuticals, Inc.122
已完成
不适用
A Study Evaluating the Safety and Efficacy of the BD211 Drug Product in β-Thalassemia Major ParticipantsHematologic DiseasesNCT05015920Shanghai BDgene Co., Ltd.2
已完成
不适用
Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia MajorBeta-ThalassemiaNCT00336362University of Washington26
招募中
3 期
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell DiseaseSickle Cell AnemiaThalassemiaSickle Cell DiseaseNCT05477563Vertex Pharmaceuticals Incorporated26
招募中
1 期
Β-Thalassemia Treatment with KL003 Cell InjectionTransfusion-dependent Beta-ThalassemiaNCT06280378Kanglin Biotechnology (Hangzhou) Co., Ltd.41